IMV IMV Inc.

3.13
+0.02  (+1%)
Previous Close 3.11
Open 3.13
Price To Book 50.05
Market Cap 158,369,568
Shares 50,597,306
Volume 3,473
Short Ratio
Av. Daily Volume 31,950

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data June 12, 2019 at ICML. 1/6 PRs; 2/6 CRs.
DPX-Survivac and pembrolizumab (ICML 2019)
Diffuse Large Cell Lymphoma
Phase 2 top-line data due 2H 2019.
DPX-Survivac and epacadostat (DeCidE1)
Ovarian cancer
Phase 2 trial ongoing.
DPX-Survivac and pembrolizumab
Ovarian cancer
Phase 2 preliminary data due 2H 2019, with top-line data due 1H 2020.
DPX-Survivac and KEYTRUDA (pembrolizumab) - basket trial
Solid tumors
Phase 1 dosing has commenced - January 17, 2019.
DPX-NEO - neoepitopes
Ovarian cancer

Latest News

  1. IMV Inc. to Present at Two Upcoming Investor Conferences
  2. New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV’s DPX-Survivac in Combination with Merck’s Keytruda in Patients with DLBCL
  3. IMV Inc. to Provide Update on Phase 2 Clinical Results with Merck Keytruda in DLBCL by Means of Conference Call and Webcast on June 12, 2019
  4. IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival
  5. IMV to Present New Data at 2019 ASCO Annual Meeting From Its Phase 2 Clinical Trial Evaluating DPX-Survivac in Ovarian Cancer
  6. IMV Inc. to Present at Upcoming Investor Conferences
  7. IMV Announces Annual and Special Meeting of Shareholders Voting Results
  8. IMV Inc. Announces Q1 2019 Financial Results and Clinical Program Advances
  9. IMV Joins World Ovarian Cancer Coalition and Ovarian Cancer Canada in Supporting Ovarian Cancer Day 2019
  10. IMV to Provide Updated Data From Phase 2 Study Evaluating DPX-Survivac in Combination with Merck’s Keytruda® in DLBCL
  11. IMV Inc. to Announce First Quarter 2019 Results and Host a Conference Call and Webcast on May 10, 2019
  12. IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer and Other Solid Tumors
  13. IMV Inc. Issues Statement on Recent Market Activity And Provides Corporate Update
  14. IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwright Investor Conference
  15. New Preclinical Research Presented at AACR 2019 Reveals Unique Anti-Cancer Mechanism of Action Underscoring IMV’s Immunotherapy Program
  16. Initial Phase 2 Data From an IMV Clinical Study Continues to Demonstrate DPX-Survivac’s Prior Trend as a Potential Monotherapy Treatment for Advanced Ovarian Cancer
  17. IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs
  18. IMV and Centre de Recherche du CHU de Québec-Université Laval Collaboration Awarded a CQDM Grant to Develop First-in-Class Dual Target T Cell Therapy in Bladder Cancer Based on IMV’s DPX Technology
  19. IMV Researchers to Present New Preclinical Data at AACR Annual Meeting 2019